Exelixis

Traded on the St. Petersburg Stock Exchange
Exelixis, Inc. is a genomics-based drug discovery company and the producer of Cometriq for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Exelixis stock price chart
vol.
change
P/E adj.
Net profit (adj.)
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Exelixis balance sheet

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Exelixis cash flows

Report period2018 2019 2020 2021 2022 2023
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS
Adjusted EPS

Exelixis multipliers

Report period2018 2019 2020 2021 2022 2023
P/E
P/E adj.
E/P
E adj./P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Exelixis profitability

Report period2018 2019 2020 2021 2022 2023
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Exelixis assets
Exelixis cash flows

Exelixis shares

TickerNameTypeNominal valueISINPrice
EXEL:USExelixis, Inc.Common share-US30161Q1040$22.52
Exelixis news
11.05.2022
Exelixis' GAAP net income for 3 months of 2022 was $68.573 million, up 42.8 times from $1.601 million in the previous year. Revenue increased 31.7% to $355.98 million from $270.23 million a year earlier.
18.02.2022
Exelixis' GAAP net income for 2021 was $231.063 million, up 2.1 times from $111.781 million in the previous year. Revenue increased 45.2% to $1.435 billion from $0.988 billion a year earlier.
03.11.2021
Exelixis' GAAP net income for 9M 2021 was $135.897 million, up 63% from $83.393 million in the previous year. Revenues increased 37.1% to $983.83 million from $717.486 million a year earlier.
06.08.2021
Exelixis' GAAP net income for 6 months of 2021 was $97.693 million, down 15.4% from $115.433 million in the previous year. Revenue increased 34.7% to $655.407 million from $486.394 million a year earlier.
General information
Company nameExelixis
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address1851 HARBOR BAY PARKWAY ALAMEDA CA 94502 6508377000
Mailing address1851 HARBOR BAY PARKWAY ALAMEDA CA 94502
Websitewww.exelixis.com
Information disclosurewww.sec.gov